You are here: Industry Insights > CNS Pharmaceuticals

News List

FDA Approves IND Application for Brain Cancer Drug Candidate americanpharmaceuticalreview
January 07, 2021
CNS Pharmaceuticals announced the Investigational New Drug (IND) application for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (GBM) is now approved and in effect as filed with the US Food and Drug Administration ...
CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin contractpharma
October 22, 2020
Phase 2 trial will commence during the first quarter of 2021.
CNS Pharmaceuticals Completes API Shipments to Manufacturers contractpharma
July 09, 2020
Supplies active ingredients for the production of Berubicin.
FDA Grants Orphan Drug Designation for Brain Cancer Drug Berubicin contractpharma
June 16, 2020
Accelerates its development to treat malignant gliomas and provides CNS with the potential for market exclusivity.
WPD Partners with CNS on Drug Development for Coronavirus, Other Antiviral Indication americanpharmaceuticalreview
March 26, 2020
WPD Pharmaceuticals has entered into a development agreement with CNS Pharmaceuticals for the development of several preclinical drug candidates including WP1122.